

HE	Health	n & Safety	Risk Assessment Guidance					
Ref: CF:024:05	RE: Guidance on Completing a Cytotoxic Drug Risk Assessment							
Issue date:	November 2015	Revised date:	October 2023					
Author(s):	National Health & Safety Functio	National Health & Safety Function						
Legislation:	National Health & Safety Function Under the Safety Health and Welfare at Work (Carcinogens) Regulations, 2001, as amended 2015 and 2019 it is the duty of the employer to identify the hazards and assess the risks associated with the risk of exposure to carcinogens (Cat. 1A and 1B) and/or mutagens (Cat. 1A and 1B) in the workplace. For the purpose of this risk assessment, all cytotoxic drugs (to include Cat. 2 carcinogens, Cat. 2 mutagens and/or reprotoxins (including teratogens)) (Cat R1A/B and R2) will be considered as subject to the Safety, Health and Welfare at Work (Carcinogens) Regulations, 2001. All risk assessments must be in writing and include the necessary control measures to eliminate or minimise the risks documented and implemented. When conducting risk assessments where Cytotoxic Drugs are involved consideration must be paid to the risk of exposure and the means of avoiding and mitigating any such risk so far as is technically possible. It is the responsibility of local management to implement any remedial actions identified.							
Note 1:	Detailed guidance to support the Cytotoxic Drugs	e carrying out / review	of risk assessments is available in the <u>GD:002 HSE Guideline on the Safe Handling of</u>					



National Health and Safety Function, Workplace Health and Wellbeing Unit, National HR Division

Cytotoxic Drug Risk	Assessment Form - Part 1 of 2					
Division:	Source of Risk:					
HG/CHO/NAS/Function:	Primary Impact Category:					
Hospital Site/Service:	Risk Type:					
Dept/Service Site:	Name of Risk Owner (BLOCKS):					
Date of Assessment:	Signature of Risk Owner:					
Unique ID No:	Risk Co-Ordinator:					
Objective being impacted:	¹Risk Assessor(s):					
Description of Work Activity: Describe the work activity being undertaken:						
A <u>separate risk assessment</u> must be completed for powders (prior to reconstite Powders Capsules / tablets Liquids Liquids Liquids Capsules / tablets Capsules /	itution); capsules/tablets; and liquids. Tick as appropriate:					
Identify the Cytotoxic Drugs covered by this risk assessment: (Please cross ref	ference to database or attach drug list)					

¹ Risk Assessor required for OSH risks only.

National Health and Safety Function, Workplace Health and Wellbeing Unit, National HR Division

			Cytt	MOXIC DIC	ig mak As	sessment F					
² HAZARD & RISK DESCRIPTION		EXISTING CONTROL MEASURES			ACTIONS [ADDITIONAL CONTROLS] REQUIRED			³ ACTION OWNER		DUE DATE	
Describe the risk associated with the activity being undertaken and the frequency and duration of potential exposure during the task. (refer to Step 2 of GD:002 HSE Guideline on the Safe Handling of Cytotoxic Drugs 2021).		Detail the control measures in place – include all measures to eliminate or reduce the risks to include • Engineering controls • Administrative controls to include SOPs • Training • PPE • Health surveillance • Spill/Incident management For further guidance refer to Step 4 of GD:002: HSE Guideline on the Safe Handling of Cytotoxic Drugs 2021			Detail the measures necessary to eliminate or further reduce the level of risk. Consider the hierarchy of controls: Elimination / substitution/ engineering / administrative/ PPE. Consider the interim and long term measures			Enter the name of the responsible person for implementation of each control measure		Enter the date by which implementation of the additional controls to mitigate the risk are due	
⁴Inherent Risk		⁵Residual Risk		⁶ Target Risk			Risk Status				
Likelihood [1-5]	Impact [1-5]	Rating [Likelihood x Impact]	Likelihood [1-5]	Impact [1-5]	Rating [Likelihood x Impact]	Likelihood [1-5]	Impact [1-5]	Rating [Likelihood x Impact]	Open	Monitor	Closed
Inherent Risk - For OSH risk assessments document the Inherent risk only where there is no documented risk assessment with identified controls for the hazard being considered								status. •Open, i.e. a necessary •Monitor, i. manage the reviewed. •Closed, i.e.	e. existing control erisk but these no	k should be assigned a ols have been identifications are deemed adequeed to be periodically longer exists e.g. who	

² Where the risk being assessed relates to an OSH risk please ensure the HAZARD and associated risk are recorded. Other risk assessments require a risk description only.

³ Person responsible for the action.

⁴ Rating **before** consideration of existing controls.

⁵ Rating **after** consideration of existing controls.

⁶ Desired rating **after** actions.